Reducing Deaths from ACLF is a Realistic Goal

• Patients with acute decompensated cirrhosis have high morbidity/ mortality.
• Liver transplantation can save the lives of patients with acute-onchronic liver failure (ACLF).
• New therapies are under development for managing ACLF, like CARBALIVE, PRECIOSA, TLR4 antagonist, G-TAK, DIALIVE APACHE.
• Cirrhocare is a decompensated cirrhosis management in the community that provides early diagnosis, allows rapid intervention and reduces hospitalization; thus improving the quality of life.
• CARBALIVE are adsorbent beads whose unique physical structure gives functionality to remove macromolecules such as endotoxins which reduce inflammation and improves gut health. 
• DIALIVE modifies the pathophysiological process involved in the pathogenesis of ACLF.Patients with acute decompensated cirrhosis have high morbidity/ mortality.
• Liver transplantation can save the lives of patients with acute-onchronic liver failure (ACLF).
• New therapies are under development for managing ACLF, like CARBALIVE, PRECIOSA, TLR4 antagonist, G-TAK, DIALIVE APACHE.
• Cirrhocare is a decompensated cirrhosis management in the community that provides early diagnosis, allows rapid intervention and reduces hospitalization; thus improving the quality of life.
• CARBALIVE are adsorbent beads whose unique physical structure gives functionality to remove macromolecules such as endotoxins which reduce inflammation and improves gut health.
• DIALIVE modifies the pathophysiological process involved in the pathogenesis of ACLF.